Core Viewpoint - OneMedNet Corporation is advancing its commercial launch of the RWD Platform powered by Palantir Foundry, converting customer evaluations into subscriptions and reinforcing its position in the life sciences and healthcare sectors [1][4]. Group 1: Commercial Launch and Subscription Growth - The launch is driving rapid expansion of subscription contracts, including multi-year deals that represent millions in incremental recurring revenue [2]. - The OneMedNet iRWD™ network has over 2,130 healthcare sites, and as it scales, the subscription value increases due to greater scale, diversity, real-time access, and analytical depth [2][4]. Group 2: Customer Feedback and Platform Strengths - Customer feedback confirms the platform's strengths, including unmatched analytical depth, accelerated cohort feasibility, streamlined workflows, and faster onboarding of data partners [3]. - The platform provides near real-time access to comprehensive regulatory-grade multimodal RWD, enhancing study design and evidence generation [5][6]. Group 3: Investor Benefits - The commercial launch supports OneMedNet's high-margin recurring revenue model, with evaluation conversions to multi-year subscriptions expected to drive predictable growth and millions in incremental annual recurring revenue [4]. - Network expansion is anticipated to boost deal sizes and penetration in life sciences, AI, and research sectors, fueling sustained bookings [4]. Group 4: Company Overview and Industry Impact - OneMedNet is revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, impacting drugmakers, medical device innovators, and AI developers [8]. - The company's proprietary AI also anonymizes data for other industries, such as finance and retail, enhancing project de-risking and secure data sharing [9].